✦ LIBER ✦

5 BETTER SUSTAINED CONTROL OF CHRONIC GENOTYPE 1 HCV INFECTIONS WITH PEG-IFN ALFA-2A THAN WITH PEG-IFN ALFA-2B TREATMENT: RESULTS OF DAILY CLINICAL PRACTICE

✍ Scribed by A. Orlandini; V. Borghi; L. Sacchelli; A. Valli; R. Bertoni; G. Verucchi; B. Piergentili; L. Testa; P. Andreone; M. Massari; S.D. Carradori; F. Ghinelli; D. Sacchini; G. Abbati; A. Pietrangelo; C. Vandelli; C. Ferrari

Book ID: 119633970
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 62 KB
Volume: 42
Category: Article
ISSN: 1590-8658
DOI: 10.1016/s1590-8658(10)60375-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The impact of fibrosis and steatosis on

The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1–infected patients treated with Peg-IFN-alfa-2a and ribavirin

✍ H. Guedj; J. Guedj; F. Negro; M. Lagging; J. Westin; P.-Y. Bochud; S. Bibert; A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

15 TELAPREVIR (TVR) q8h OR q12h COMBINED

15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208

✍ M. Colombo; M.G. Rumi; G. Carosi; M. Puoti; P. Marcellin; X. Forns; T. Göser; P. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Sa1053 Age-Dependent Rise in Early Hemog

Sa1053 Age-Dependent Rise in Early Hemoglobin (HB) Decline Contributes to a Higher Frequency of Anemia in Elder Patients Treated With Peginterferon Alfa-2B (Peg2b)/Ribavirin (RBV) for Chronic HCV Genotype 1 (G1) Infection

✍ Teuber, Gerlinde; Mauss, Stefan; Hüppe, Dietrich; Zehnter, Elmar; Manns, Michael 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 170 KB

PEG12000-IFN alfa 2B 0.5 mcg/kg + ribavi

PEG12000-IFN alfa 2B 0.5 mcg/kg + ribavirin 800 mg/day vs. PEG12000-IFN alfa 2B 1.5 mcg/kg + ribavirin 800 mg/day for 48 weeks for treatment of patients with hepatitis C who failed or relapsed after treatment with combination therapy (rebetron)-interim results: Douglas D Dalke, Gastroenterology Specialties, Lincoln, NE; Jeremiah Donovan, Creighton University, Omaha, NE; John Goff, Rocky Mountain Gastroenterology, Denver, CO; Howard Monsour, Gastroenterology & Liver Assoc, Houston, TX; Terry Box, Mountain West Gastroenterology, Salt Lake City, UT; Andre Triebling, Arapahoe Gastroenterology, Denver, CO; Douglas Brouillette, Internal Medicine Assoc, Omaha, NE; Robert Levine, Boulder Medical Ctr, Boulder, CO; Lawrence Kim, South Denver Gastroenterology, Englewood, CO; Mark Malliard, Univ of NE Dept of Hepatology, Omaha, NE

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB